American Diabetes Association Professional Practice C. 13. Older Adults: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S266–S82.

Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–23.

Article  CAS  PubMed  Google Scholar 

Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342–56.

Article  PubMed  PubMed Central  Google Scholar 

Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy in older patients with type 2 diabetes. Aging Clin Exp Res. 2022;34(9):1969–83.

Article  PubMed  PubMed Central  Google Scholar 

Merel SE, Paauw DS. Common drug side effects and drug-drug interactions in elderly adults in primary care. J Am Geriatr Soc. 2017;65(7):1578–85.

Article  PubMed  Google Scholar 

Sinclair AJ, Abdelhafiz AH, Forbes A, Munshi M. Evidence-based diabetes care for older people with type 2 diabetes: a critical review. Diabet Med. 2019;36(4):399–413.

Article  CAS  PubMed  Google Scholar 

Gates BJ, Walker KM. Physiological changes in older adults and their effect on diabetes treatment. Diabetes Spectr. 2014;27(1):20–8.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S181–S206.

DeCarlo K, Wallia A, Kang RH, Cooper A, Cherupally M, Harris SA, et al. Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin. BMC Geriatr. 2022;22(1):97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Group GSR, Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, et al. Glycemia reduction in type 2 diabetes—glycemic outcomes. N Engl J Med. 2022;387(12):1063–74.

Article  Google Scholar 

May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28(7):601–31.

Article  CAS  PubMed  Google Scholar 

Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmoller J, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005;60(1):103–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther. 2010;87(1):52–6.

Article  CAS  PubMed  Google Scholar 

Triplitt C. Drug interactions of medications commonly used in diabetes. Diabetes Spectr. 2006;19(4):202–11.

Article  Google Scholar 

Arnouts P, Bolignano D, Nistor I, Bilo H, Gnudi L, Heaf J, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014;29(7):1284–300.

Article  CAS  PubMed  Google Scholar 

Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Gagne JJ. A case-crossover-based screening approach to identifying clinically relevant drug-drug interactions in electronic healthcare data. Clin Pharmacol Ther. 2019;106(1):238–44.

Article  CAS  PubMed  Google Scholar 

Chen C, Pham Nguyen TP, Hughes JE, Hennessy S, Leonard CE, Miano TA, et al. Evaluation of drug-drug interactions in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 2025;34(1):e70088.

Article  CAS  PubMed  Google Scholar 

Bots SH, Brown J, Wong AYS, Martin I, Douglas I, Klungel OH, et al. Core concepts: self-controlled designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2025;34(1):e70071.

Article  PubMed  PubMed Central  Google Scholar 

Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53.

Article  CAS  PubMed  Google Scholar 

Hallas J, Pottegard A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275(6):581–9.

Article  CAS  PubMed  Google Scholar 

Min JY, Presley CA, Wharton J, Griffin MR, Greevy RA Jr., Hung AM, et al. Accuracy of a composite event definition for hypoglycemia. Pharmacoepidemiol Drug Saf. 2019;28(5):625–31.

Article  PubMed  PubMed Central  Google Scholar 

Karter AJ, Warton EM, Moffet HH, Ralston JD, Huang ES, Miller DR, et al. Revalidation of the hypoglycemia risk stratification tool using ICD-10 codes. Diabetes Care. 2019;42(4):e58–9.

Article  PubMed  PubMed Central  Google Scholar 

Consiglio GP, Burden AM, Maclure M, McCarthy L, Cadarette SM. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations. Pharmacoepidemiol Drug Saf. 2013;22(11):1146–53.

Article  PubMed  Google Scholar 

Quinn KJ, Shah NH. A dataset quantifying polypharmacy in the United States. Sci Data. 2017;4(31):170167.

Article  PubMed  PubMed Central  Google Scholar 

Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel–Haenszel procedure. J Am Stat Assoc. 1963;58(303):690–700.

Google Scholar 

Mc NQ. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12(2):153–7.

Article  Google Scholar 

Bykov K, Franklin JM, Li H, Gagne JJ. Comparison of self-controlled designs for evaluating outcomes of drug-drug interactions: simulation study. Epidemiology. 2019;30(6):861–6.

Article  PubMed  PubMed Central  Google Scholar 

Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013;24(3):375–8.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association Professional Practice C. 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S128–S45.

Benjamini Y, Heller R, Yekutieli D. Selective inference in complex research. Philos Trans A Math Phys Eng Sci. 1906;2009(367):4255–71.

Google Scholar 

Storey JD. A direct approach to false discovery rates. J R Stat Soc Series B Stat Methodol. 2002;64(3):479–98.

Article  Google Scholar 

Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med. 2014;174(10):1605–12.

Article  PubMed  PubMed Central  Google Scholar 

Lee S, Ock M, Kim HS, Kim H. Effects of co-administration of sulfonylureas and antimicrobial drugs on hypoglycemia in patients with type 2 diabetes using a case-crossover design. Pharmacotherapy. 2020;40(9):902–12.

Article  CAS  PubMed  Google Scholar 

Kennedy KE, Teng C, Patek TM, Frei CR. Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). Drug Saf. 2020;43(4):363–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liao SH, Hu SY, How CK, Hsieh VC, Chan CM, Chiu CS, et al. Risk for hypoglycemic emergency with levofloxacin use, a population-based propensity score matched nested case-control study. PLoS ONE. 2022;17(4):e0266471.

Article